Skip to main content
Erschienen in: Cancer Causes & Control 5/2009

01.07.2009 | Original Paper

Vitamin and mineral use and risk of prostate cancer: the case–control surveillance study

verfasst von: Yuqing Zhang, Patricia Coogan, Julie R. Palmer, Brian L. Strom, Lynn Rosenberg

Erschienen in: Cancer Causes & Control | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Many studies have evaluated the association between vitamin and mineral supplement use and the risk of prostate cancer, with inconclusive results.

Methods

The authors examined the relation of use of multivitamins as well as several single vitamin and mineral supplements to the risk of prostate cancer risk among 1,706 prostate cancer cases and 2,404 matched controls using data from the hospital-based case–control surveillance study conducted in the United States. Odds ratios (OR) and 95% confidence intervals (CI) for risk of prostate cancer were estimated using conditional logistic regression model.

Results

For use of multivitamins that did not contain zinc, the multivariable odds ratios of prostate cancer were 0.6 for 1–4 years, 0.8 for 5–9 years, and 1.2 for 10 years or more, respectively (p for trend = 0.70). Men who used zinc for ten years or more, either in a multivitamin or as a supplement, had an approximately two-fold (OR = 1.9, 95% CI: 1.0, 3.6) increased risk of prostate cancer. Vitamin E, beta-carotene, folate, and selenium use were not significantly associated with increased risk of prostate cancer.

Conclusion

The finding that long-term zinc intake from multivitamins or single supplements was associated with a doubling in risk of prostate cancer adds to the growing evidence for an unfavorable effect of zinc on prostate cancer carcinogenesis.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef
4.
Zurück zum Zitat Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF (2004) Dietary supplement use by US adults: data from the national health and nutrition examination survey, 1999–2000. Am J Epidemiol 160:339–349. doi:10.1093/aje/kwh207 PubMedCrossRef Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF (2004) Dietary supplement use by US adults: data from the national health and nutrition examination survey, 1999–2000. Am J Epidemiol 160:339–349. doi:10.​1093/​aje/​kwh207 PubMedCrossRef
7.
Zurück zum Zitat NIH State-of-the-Science Panel (2006) National Institutes of Health State-of-the-science conference statement: multivitamin/mineral supplements and chronic disease prevention. Ann Intern Med 145:364–371. doi:10.1001/archinte.145.2.364 NIH State-of-the-Science Panel (2006) National Institutes of Health State-of-the-science conference statement: multivitamin/mineral supplements and chronic disease prevention. Ann Intern Med 145:364–371. doi:10.​1001/​archinte.​145.​2.​364
9.
Zurück zum Zitat Heinonen OP, Albanes D, Virtamo J et al (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446. doi:10.1093/jnci/90.6.440 PubMedCrossRef Heinonen OP, Albanes D, Virtamo J et al (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446. doi:10.​1093/​jnci/​90.​6.​440 PubMedCrossRef
10.
Zurück zum Zitat Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE (1999) Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8:887–892PubMed Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE (1999) Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8:887–892PubMed
11.
Zurück zum Zitat Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 8:893–899PubMed Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 8:893–899PubMed
12.
Zurück zum Zitat Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL (2003) Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 95:1004–1007PubMed Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL (2003) Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 95:1004–1007PubMed
13.
Zurück zum Zitat Rodriguez C, Jacobs EJ, Mondul AM, Calle EE, McCullough ML, Thun MJ (2004) Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 13:378–382PubMed Rodriguez C, Jacobs EJ, Mondul AM, Calle EE, McCullough ML, Thun MJ (2004) Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 13:378–382PubMed
15.
Zurück zum Zitat Kirsh VA, Hayes RB, Mayne ST et al (2006) Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 98:245–254PubMed Kirsh VA, Hayes RB, Mayne ST et al (2006) Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 98:245–254PubMed
17.
Zurück zum Zitat Lawson KA, Wright ME, Subar A et al (2007) Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99:754–764. doi:10.1093/jnci/djk177 PubMedCrossRef Lawson KA, Wright ME, Subar A et al (2007) Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99:754–764. doi:10.​1093/​jnci/​djk177 PubMedCrossRef
18.
21.
22.
Zurück zum Zitat Hartman TJ, Albanes D, Pietinen P et al (1998) The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 7:335–340PubMed Hartman TJ, Albanes D, Pietinen P et al (1998) The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 7:335–340PubMed
23.
Zurück zum Zitat Kolonel LN, Yoshizawa CN, Hankin JH (1988) Diet and prostatic cancer: a case–control study in Hawaii. Am J Epidemiol 127:999–1012PubMed Kolonel LN, Yoshizawa CN, Hankin JH (1988) Diet and prostatic cancer: a case–control study in Hawaii. Am J Epidemiol 127:999–1012PubMed
25.
Zurück zum Zitat Stevens VL, Rodriguez C, Pavluck AL, McCullough ML, Thun MJ, Calle EE (2006) Folate nutrition and prostate cancer incidence in a large cohort of US men. Am J Epidemiol 163:989–996. doi:10.1093/aje/kwj126 PubMedCrossRef Stevens VL, Rodriguez C, Pavluck AL, McCullough ML, Thun MJ, Calle EE (2006) Folate nutrition and prostate cancer incidence in a large cohort of US men. Am J Epidemiol 163:989–996. doi:10.​1093/​aje/​kwj126 PubMedCrossRef
27.
Zurück zum Zitat The alpha-tocopherol, beta carotene cancer prevention study group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035. doi:10.1056/NEJM199404143301501 The alpha-tocopherol, beta carotene cancer prevention study group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035. doi:10.​1056/​NEJM199404143301​501
28.
Zurück zum Zitat West DW, Slattery ML, Robison LM, French TK, Mahoney AW (1991) Adult dietary intake and prostate cancer risk in Utah: a case–control study with special emphasis on aggressive tumors. Cancer Causes Control 2:85–94. doi:10.1007/BF00053126 PubMedCrossRef West DW, Slattery ML, Robison LM, French TK, Mahoney AW (1991) Adult dietary intake and prostate cancer risk in Utah: a case–control study with special emphasis on aggressive tumors. Cancer Causes Control 2:85–94. doi:10.​1007/​BF00053126 PubMedCrossRef
29.
Zurück zum Zitat Rosenberg L, Coogan P, Palmer J (2005) Case–control surveillance. In: Strom BL (ed) Pharmacoepidemiology. Wiley, Chichester, pp 185–202 Rosenberg L, Coogan P, Palmer J (2005) Case–control surveillance. In: Strom BL (ed) Pharmacoepidemiology. Wiley, Chichester, pp 185–202
30.
Zurück zum Zitat Weinstein SJ, Wright ME, Pietinen P et al (2005) Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 97:396–399PubMedCrossRef Weinstein SJ, Wright ME, Pietinen P et al (2005) Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 97:396–399PubMedCrossRef
32.
Zurück zum Zitat Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. JAMA 276:1957–1963. doi:10.1001/jama.276.24.1957 PubMedCrossRef Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. JAMA 276:1957–1963. doi:10.​1001/​jama.​276.​24.​1957 PubMedCrossRef
33.
Zurück zum Zitat Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R et al (2003) Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine. Cancer Epidemiol Biomarkers Prev 12:1271–1272PubMed Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R et al (2003) Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine. Cancer Epidemiol Biomarkers Prev 12:1271–1272PubMed
34.
Zurück zum Zitat Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P (2005) Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer 113:819–824. doi:10.1002/ijc.20646 PubMedCrossRef Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P (2005) Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer 113:819–824. doi:10.​1002/​ijc.​20646 PubMedCrossRef
35.
Zurück zum Zitat Johansson M, Appleby PN, Allen NE et al (2008) Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev 17:279–285. doi:10.1158/1055-9965.EPI-07-0657 PubMedCrossRef Johansson M, Appleby PN, Allen NE et al (2008) Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev 17:279–285. doi:10.​1158/​1055-9965.​EPI-07-0657 PubMedCrossRef
36.
Zurück zum Zitat Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P (1999) Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 40:200–207. doi:10.1002/(SICI)1097-0045(19990801)40:3<200::AID-PROS8>3.0.CO;2-3PubMedCrossRef Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P (1999) Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 40:200–207. doi:10.1002/(SICI)1097-0045(19990801)40:3<200::AID-PROS8>3.0.CO;2-3PubMedCrossRef
37.
Zurück zum Zitat Ishii K, Usui S, Sugimura Y et al (2001) Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 92:49–54. doi:10.1002/1097-0215(200102)9999:9999<::AID-IJC1161>3.0.CO;2-SPubMedCrossRef Ishii K, Usui S, Sugimura Y et al (2001) Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 92:49–54. doi:10.1002/1097-0215(200102)9999:9999<::AID-IJC1161>3.0.CO;2-SPubMedCrossRef
38.
40.
Zurück zum Zitat Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS (1996) Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56:218–222PubMed Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS (1996) Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56:218–222PubMed
41.
Zurück zum Zitat Boissier S, Ferreras M, Peyruchaud O et al (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949–2954PubMed Boissier S, Ferreras M, Peyruchaud O et al (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949–2954PubMed
42.
Zurück zum Zitat Holmes MD, Pollak MN, Willett WC, Hankinson SE (2002) Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11:852–861PubMed Holmes MD, Pollak MN, Willett WC, Hankinson SE (2002) Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11:852–861PubMed
45.
Metadaten
Titel
Vitamin and mineral use and risk of prostate cancer: the case–control surveillance study
verfasst von
Yuqing Zhang
Patricia Coogan
Julie R. Palmer
Brian L. Strom
Lynn Rosenberg
Publikationsdatum
01.07.2009
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 5/2009
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9282-y

Weitere Artikel der Ausgabe 5/2009

Cancer Causes & Control 5/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.